Search | Clinical Trials Finder

Conditions: Dyspepsia
Interventions: dexloxiglumide, Nexium (esomeprazole); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adverse Drug Reaction
Interventions: Pharmacogenetic Intervention Arm (pharmacogenetic testing); Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Gastro-esophageal Reflux
Interventions: Esomeprazole (Nexium); Drug
Lead sponsor: Douglas Trask; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Solid Tumors, Lymphoma
Interventions: Alisertib, Esomeprazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Peptic Ulcer
Interventions: AGN 201904, esomeprazole; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: GERD
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 19
States / cities: Tucson, Arizona • Anaheim, California • Orange, California + 16 more

Conditions: Healthy Participants
Interventions: INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Nausea, Vomiting, Abdominal Pain
Interventions: esomeprazole (PPI); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastroesophageal Reflux Disease
Interventions: Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Anaheim, California • Orange, California • San Diego, California + 4 more

Conditions: Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
Interventions: Secretol, Nexium; Drug
Lead sponsor: Effexus Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Volunteers
Interventions: Brensocatib, Rifampin, Esomeprazole; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer
Interventions: Oral Taxane; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Timeline: Started 2006
U.S. locations: 3
States / cities: Newark, Delaware • Louisville, Kentucky • Las Vegas, Nevada

Conditions: Chronic Pancreatitis
Interventions: Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pharmacokinetics of Isavuconazole, Healthy Subjects
Interventions: Isavuconazole, Esomeprazole; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
Interventions: 24 hour pH testing; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: NSAIDs, Upper GI Symptoms
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 32
States / cities: Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 29 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Moline, Illinois

Conditions: Healthy Study Participants
Interventions: UCB0599, Esomeprazole, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Barrett's Esophagus
Interventions: Esomeprazole, Lansoprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Phoenix, Arizona • Tucson, Arizona • North Chicago, Illinois + 9 more

Conditions: Healthy Participants
Interventions: BMS-986278 Tablet, Esomeprazole, BMS-986278 suspension; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: GERD
Interventions: Antacids; Drug
Lead sponsor: Digestive & Liver Disease Specialists; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: NSAIDs, Upper GI Symptoms
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 31
States / cities: Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more

Search by objective public record fields.

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

YouScript IMPACT Registry

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs